Head And Neck Cancer

ASCO: Undertreatment Seen for Women With Head & Neck Cancer

June 07, 2018

In generalized competing event analysis, the relative hazard ratio for death from HNC versus other causes was increased for female patients (adjusted relative hazard ratio, 1.92), indicating that female patients may be undertreated.

Opioid Rx Patterns Examined for Head and Neck, Lung and Colon Cancer

March 12, 2018

The researchers identified 168 prescriptions associated with HNCA and 571 with LCCA diagnoses. Compared to patients with LCCA, patients with HNCA had significantly increased odds of being prescribed an opioid (odds ratio, 1.68).

FDA Approves New Dosing Option for Opdivo

By March 06, 2018

This approval will provide healthcare professionals the flexibility to customize patient care.

Outcomes Assessed for HPV-Related Head, Neck CA Requiring Resections

February 12, 2018

Surgery and adjuvant therapy used for invasive nodal disease requiring extensive neck dissection. Researchers found that regional recurrences were seen in 6% of patients, and 17% experienced distant recurrences.

Swallowable Alternative to Endoscopy for Barrett's Esophagus Detection

January 23, 2018

The researchers found that for discriminating BE-related metaplasia and neoplasia cases versus normal individuals, CCNA1 DNA methylation had an area under the curve of 0.95, which was identical to that of VIM DNA methylation.

Significant Links Between Depressive Symptoms and Mortality in CA Patients

January 23, 2018

The researchers found that greater depressive symptoms were associated with significantly shorter survival (hazard ratio, 0.868; P<0.001), higher rates of chemoradiation interruption (odds ratio, 0.865; P=0.010).

Avastin Gains Full FDA Approval for Recurrent Glioblastoma

By December 06, 2017

The conversion from provisional to full approval was based on totality of evidence of Avastin in glioblastoma.

Survival With Combo Bevacizumab + Lomustine Tx Examined in Glioblastoma

November 17, 2017

However, locally assessed progression-free survival was 2.7 months longer in the combination group than in the monotherapy group.

Do Higher Volume Facilities Have Better NPC Survival Outcomes?

November 06, 2017

Receiving care at an HVF independently predicted higher overall survival (hazard ratio, 0.85).

First Biosimilar For Cancer Treatment Approved

By September 14, 2017

The approval was based on evidence from animal study data, human pharmacokinetic and pharmacodynamics data, and clinical immunogenicity data which demonstrated Mvasi is a biosimilar to Avastin.

Accuracy of EBV DNA Examined as Nasopharyngeal CA Biomarker

August 10, 2017

Overall, 1.5% of all patients and 27.8% of those who initially tested positive had persistently positive results on the repeated sample four weeks later.

Vaccination Protection Assessed for Oral HPV

May 19, 2017

Data from 2,627 Americans, aged 18 to 33, were analyzed to assess the effect of self-reported receipt of at least one dose of an HPV vaccine on oral HPV infection.

Copanlisib Granted Priority Review for Follicular Lymphoma

By May 17, 2017

Orphan designation has also been granted to copanlisib for the treatment of splenic, nodal, and extranoldal subtypes of marginal zone lymphoma.

Vaccine-Chemo Combo Promising for Glioblastoma

April 17, 2017

Four of the 11 patients in this study survived for more than 5 years after vaccine/chemotherapy treatment.

Distinction Between Cancer Occurrence in U.S.-, African-Born Blacks

April 14, 2017

Research suggests differences in environmental, cultural, social, genetic factors

Wearable Device Plus Temozolomide Tx May Improve Survival in Glioblastoma

April 03, 2017

The researchers found that the median progression-free survival was 6.7 and 4.0 months for patients treated with TTFields/TMZ and TMZ alone, respectively.

FDA Grants Opdivo Accelerated Approval For Urothelial Carcinoma

By February 03, 2017

The FDA has approved Opdivo (nivolumab; Bristol-Myers Squibb) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or after platinum-based chemotherapy or for those who have disease progression within 12 months of neoadjuvant or adjuvant platinum-based chemotherapy.

Predictive Factors in Laryngeal SCC Recurrence

December 14, 2016

For patients with laryngeal squamous cell carcinoma (SCC), factors predictive of recurrence include neck metastasis at presentation and nonsurgical treatment, according to a study published online November 30 in Head & Neck.

Molecular Alterations May ID Survival in NSCLC With Brain Metastases

November 21, 2016

An updated index incorporating gene and molecular alterations can predict survival in non-small-cell lung cancer (NSCLC) with brain metastases.

Opdivo Approved to Treat Head and Neck Cancer

By November 11, 2016

The Food and Drug Administration (FDA) has approved a new indication for Opdivo (nivolumab injection; Bristol-Myers Squibb).

Outcomes of Recurrent Glioblastoma Predicted With Radiomic-Based Method

October 11, 2016

A radiomic-based approach can be used to generate a prediction model for stratifying treatment outcome among patients with recurrent glioblastoma prior to bevacizumab treatment, according to a study published online in Clinical Cancer Research.

Nivolumab vs. Standard Single-Agent Therapy Assessed in Head, Neck CA

October 11, 2016

Nivolumab is associated with longer overall survival than standard single-agent therapy in patients with platinum-refractory, recurrent squamous-cell carcinoma of the head and neck, according to a study published online in the New England Journal of Medicine.